Modeling of trough plasma bismuth concentrations
- PMID: 9353695
- DOI: 10.1023/a:1025771811143
Modeling of trough plasma bismuth concentrations
Abstract
Disposition pharmacokinetics of bismuth following oral dosing of ranitidine bismuth citrate are complicated and variable. An analysis of data from healthy volunteers suggests a model with three disposition compartments and first-order absorption. Patient data are pooled from 10 separate studies and consist of 1140 trough concentrations measured in 802 patients following dosing of 2 to 12 weeks duration. There are therefore insufficient data to obtain reliable parameter estimates for the full model and we use instead a much reduced model and an informative prior based on the volunteer data. Individual parameter estimates from this model can then be used to establish covariate relationships. Trough concentrations were influenced by the coadministration of clarithromycin and by creatinine clearance. A simulation study was carried out to check the validity of the estimates obtained from the reduced model. We carry out analysis via Bayesian sampling-based techniques. Throughout, we use predictive distributions for both diagnostic and inference purposes. In particular, we determine predicted distributions for the Cmax, Cmin and AUC characteristics of new individuals.
Similar articles
-
Pharmacokinetics of bismuth and ranitidine following multiple doses of ranitidine bismuth citrate.Br J Clin Pharmacol. 1996 Aug;42(2):207-11. doi: 10.1046/j.1365-2125.1996.39310.x. Br J Clin Pharmacol. 1996. PMID: 8864319 Free PMC article. Clinical Trial.
-
Pharmacokinetics of bismuth and ranitidine following single doses of ranitidine bismuth citrate.Br J Clin Pharmacol. 1996 Aug;42(2):201-5. doi: 10.1046/j.1365-2125.1996.03929.x. Br J Clin Pharmacol. 1996. PMID: 8864318 Free PMC article. Clinical Trial.
-
Distribution of bismuth in the rat after oral dosing with ranitidine bismuth citrate and bismuth subcitrate.J Pharm Pharmacol. 1998 Mar;50(3):279-83. doi: 10.1111/j.2042-7158.1998.tb06861.x. J Pharm Pharmacol. 1998. PMID: 9600719
-
Ranitidine bismuth citrate plus clarithromycin for the eradication of H. pylori.J Physiol Pharmacol. 1997 Sep;48 Suppl 4:47-58. J Physiol Pharmacol. 1997. PMID: 9440055 Review.
-
Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail.Aliment Pharmacol Ther. 2002 Jun;16(6):1047-57. doi: 10.1046/j.1365-2036.2002.01276.x. Aliment Pharmacol Ther. 2002. PMID: 12030945 Review.
Cited by
-
Clinical pharmacokinetics of clarithromycin.Clin Pharmacokinet. 1999 Nov;37(5):385-98. doi: 10.2165/00003088-199937050-00003. Clin Pharmacokinet. 1999. PMID: 10589373 Review.
-
Propagation of population pharmacokinetic information using a Bayesian approach: comparison with meta-analysis.J Pharmacokinet Pharmacodyn. 2005 Aug;32(3-4):401-18. doi: 10.1007/s10928-005-0048-9. J Pharmacokinet Pharmacodyn. 2005. PMID: 16320100
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources